Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Initial chest radiograph scores inform COVID-19 status, intensive care unit admission and need for mechanical ventilation

B. Shen, M. Hoshmand-Kochia, A. Abbasi, S. Glass, Z. Jiang, A.J. Singer, H.C. Thode, H. Li, W. Hou, T.Q. Duong

AIM: To evaluate whether portable chest radiography (CXR) scores are associated with coronavirus disease 2019 (COVID-19) status and various clinical outcomes.

MATERIALS AND METHODS: This retrospective study included 500 initial CXR from COVID-19-suspected patients. Each CXR was scored based on geographic extent and degree of opacity as indicators of disease severity. COVID-19 status and clinical outcomes including intensive care unit (ICU) admission, mechanical ventilation, mortality, length of hospitalisation, and duration on ventilator were collected. Multivariable logistic regression analysis was performed to evaluate the relationship between CXR scores and COVID-19 status, CXR scores and clinical outcomes, adjusted for code status, age, gender and co-morbidities.

RESULTS: The interclass correlation coefficients amongst raters were 0.94 and 0.90 for the extent score and opacity score, respectively. CXR scores were significantly (p < 0.01) associated with COVID-19 positivity (odd ratio [OR] = 1.49; 95% confidence interval [CI]: 1.27 - 1.75 for extent score and OR = 1.75; 95% CI: 1.42 - 2.15 for opacity score), ICU admission (OR = 1.19; 95% CI: 1.09 - 1.31 for extent score and OR = 1.26; 95% CI: 1.10 - 1.44 for opacity score), and invasive mechanical ventilation (OR = 1.22; 95% CI: 1.11 - 1.35 for geographic score and OR = 1.21; 95% CI: 1.05 - 1.38 for opacity score). CXR scores were not significantly different between survivors and non-survivors after adjusting for code status (p>0.05). CXR scores were not associated with length of hospitalisation or duration on ventilation (p>0.05).

CONCLUSIONS: Initial CXR scores have prognostic value and are associated with COVID-19 positivity, ICU admission, and mechanical ventilation.
Introduction

Coronavirus disease 2019 (COVID-19), an infectious disease that can cause severe respiratory illness,1–3 has already infected 13 million people and killed more than 570,000 worldwide.4 COVID-19 continues to strain resources in many hospitals around the world. Lung imaging plays an important role in the management of patients during COVID-19 pandemic. Although reverse transcription polymerase chain reaction (RT-PCR) of a nasopharyngeal or oropharyngeal swab specimen is a reference standard5–9 for diagnosing COVID-19 infection, it has a long turnaround time and high false-negative rate.6 Newer tests, such as the lateral flow tests, have rapid turnaround time, but low sensitivity.7 Computed tomography (CT)8 was used in China early on in the pandemic when RT-PCR was less reliable, and CT offers high sensitivity and faster turnaround time; however, CT is prone to cross-contamination and, thus, it is not widely used in the context of COVID-19 in the United States and elsewhere in the world. In addition, CT is not readily accessible in many parts of the world and poses the risk of radiation exposure to patients. By contrast, chest radiography (CXR) is convenient and can be readily disinfected between uses, is more accessible, and has a lower radiation dose than CT, although it has lower sensitivity than CT. Nonetheless, CXRs show characteristic ground-glass opacities and/or consolidation in the lungs associated with COVID-19 infection.9 CXR is often one of the very first clinical assessments that suspected COVID-19 patients receive. Under the appropriate context and along with other clinical assessment, CXR can facilitate diagnosis and triage patients while RT-PCR results are pending. CXR is also well suited to monitor disease progression during hospitalisation, such as sicker patients in the ICU, which is very crucial as those patients cannot be readily moved to the CT machine.

To date, CXR score has not been widely used for staging of disease severity of COVID-19 lung infection in clinical practice. Although a few recent studies have related initial CXR scores of COVID-19 patients to various clinical outcomes, such as ICU admission, need for mechanical ventilation, mortality, length of hospitalisation, and duration on ventilator,10–14 the results are inconsistent and controversial. The CXR scoring methods varied, and demographics and comorbidities were accounted for in some but not other studies. No studies to date have accounted for whether patients were removed from aggressive therapies due to having a “do not resuscitate” order (i.e., code status), which confound data interpretation and compromise the prognostic value of CXR scores. As such, the potential of CXR to stage disease severity of COVID-19 lung infection is not yet fully realised.

The goal of this study was to further investigate the association of CXR scores of disease severity with COVID-19 status, ICU admission, need for mechanical ventilation, mortality, length of hospitalisation, and duration on ventilator. The types of CXR scores were established carefully for disease severity, one based on geographical extent of involvement and the other based on degree of opacity, with consensus amongst a group of chest radiologists and residents. Analysis accounted for patients’ code status, demographics, and co-morbidities.

Materials and methods

Patient selection and inclusion criteria

This is an institutional review board approved retrospective study from University Hospital (for blind review) with waiver of informed consent. There were 4,997 persons under investigation (PUI) for COVID-19, who presented to the emergency department (ED) between 8 March 2020 and 20 April 2020. Only patients with known COVID-19 PCR results and CXRs taken within the first 3 days of ED visit were included. Patients with incomplete information regarding comorbidities were excluded from the study. If there were multiple CXRs for one patient, the one closest to the ED visit was used. This resulted in 500 CXRs with the majority (90%) of the CXRs taken on the day of ED admission from 500 PUIs taken between 8 March 2020 and 13 April 2020 for scoring and analysis.

Clinical data collection

Data were extracted from the electronic medical records both automatically and manually by trained data abstractors via commercial software Cerner’s HealtheIntent and established diagnostic codes (such as ICD10 and LOINC codes). These data included patients’ demographic information (age and sex), co-morbidities (hypertension [hypertension], diabetes mellitus [DM], asthma, coronary artery disease [CAD], chronic obstructive pulmonary disease [COPD], congestive heart failure [CHF], cancer, immunosuppression, chronic kidney disease [CKD]), clinical outcomes (ICU admission, need for invasive mechanical ventilation, mortality, length of hospital stay, and duration on mechanical ventilator). Data also included patient’s duration of symptom onset prior to ED presentation and patient’s code status (in which full code indicates all resuscitation interventions to be performed).

Imaging collection and analysis

To establish the disease severity score, a group of four board-certified chest radiologists of 10–20 years of experience and two radiology residents in training worked together to reach consensus by evaluating 12 images of portable CXRs of COVID-19 patients, which was part of the 500 CXRs. The same chest radiologists and residents scored the 500 CXRs for disease severity using the following criteria based on geographical extent and degree of opacity. The extent score of 0–4 was assigned to each of the right and left lungs depending on the extent of involvement with
ground glass opacities or consolidation: 0 = no involvement; 1 = <25%; 2 = 25–50%; 3 = 51–75%; 4 = >75% involvement. The opacity score of 0–4 was assigned to each of the right and left lungs as: 0 = no opacity; 1 = ground glass opacity; 2 = mix of consolidation and ground glass opacity (<50% consolidation); 3 = mix of consolidation and ground glass opacity (>50% consolidation); 4 = complete white-out. The right and left lung were scored separately and added together. In short, extent score ranged from 0–8, the opacity score ranged from 0–8. In addition, the sum of these two types of scores (0–16) and the product of the two types of scores (0–64) were computed. To minimise bias, the raters were blinded to the clinical data while scoring the CXRs. Each CXR was scored by two raters independently and the mean of the scores of two raters were calculated.

Statistical methods and performance evaluation

Statistical analysis was performed with IBM SPSS software (Chicago, IL, USA). Intraclass correlation coefficient was calculated to assess inter-reader agreement of the CXR scores. Means and standard deviations of extent score, opacity score, sum of extent and opacity score, product of extent and opacity score were calculated. Multivariable logistic regression analysis were performed to analyse the relationships between CXR scores with ICU admission, mortality, need for ventilation, and gender. Odds ratios were also computed. Linear regression analysis was performed to analyse the correlation between CXR scores and age, length of hospital stay, and duration on ventilation. A p<0.05 is taken to be statistically significant unless otherwise specified.

Results

Fig 1 shows the flowchart of patient selection and outcomes of the 500 PUI. Of the 4,997 PUI, after excluding patients with unknown COVID-19 status, incomplete information on co-morbidities, and no CXR within 3 days of ED visit, 500 PUIs were investigated (59 COVID-19 negative, 441 COVID-19 positive). Of the 441 COVID-19 positive patients, eight were discharged from the ED, two died in the ED, 377 were admitted to the regular ward, and 54 were admitted directly to the ICU. Of the 377 patients initially admitted to the regular ward, 255 remained on the regular ward and 122 were subsequently upgraded to the ICU. Of those who remained on the regular ward, 227 were discharged and 28 died. Of the ICU group, 98 were discharged, 59 died while 19 remained on the ICU without a final status.

Table 1 shows the demographics and co-morbidities of all the patients in this study.

Examples of CXRs with different extent and opacity scores are demonstrated in Fig 2. CXRs of COVID-19 positive patients showed hazy opacities and/or airspace consolidation, with predominance of bilateral, peripheral and lower lung zone distribution. Each CXR was scored by two raters. The inter-reader agreement assessed by intraclass correlation coefficient, which was 0.94 (95% CI: 0.93–0.95) for the extent score, and 0.90 (95% CI: 0.88–0.92) for the opacity
score. The Pearson’s correlation coefficient between the extent score and opacity score was 0.82 ($p=0.01$).

The extent score, opacity score, sum of extent and opacity score, product of extent and opacity score scores were significantly higher in COVID-19 positive patients compared to COVID-19 negative patients, with the odd ratios ranging from 1.03 to 1.22 after adjusting for age, sex, and co-morbidities (Table 3b). The majority of the ICU patients (85%) were on invasive mechanical ventilators.

For the general floor admission cohort, all CXR scores were significantly higher in non-survivors than in survivors with the odd ratios ranging from 1.09 to 2.18, after adjusting for age, sex, and co-morbidities (Table 4a). For the ICU cohort, opacity score, sum of extent, and opacity score, and product of extent and opacity score were significantly higher in non-survivors than in survivors with the odds ratios ranging from 1.04 to 1.38, after adjusting for age, sex and co-morbidities, but not the extent score (Table 4b).

Mortality with respect to the patient’s code status was also analysed. Amongst the regular ward patients, 91% of the survivors and 7% of the non-survivors were full code, which indicates all resuscitation interventions to be performed. Amongst the ICU patients, 93% of the survivors and 27% of the non-survivors were full code. CXR scores between survivors and non-survivors in ICU who were full code were not significantly different (Table 4c). There were only two non-survivors on the general floor who were full code, and they were not further analysed.

CXR scores were not associated with the length of hospital stay both for the regular ward patients ($R=0.04$ for extent score and $R=0.12$ for opacity score, $p>0.05$) and the ICU patients ($R=−0.01$ for extent score and $R=−0.18$ for opacity score, $p>0.05$) when regular patients and ICU

### Table 1
Demographics and co-morbidities of the 500 persons under investigation whose chest radiographs were used in this study.

| Co-morbidities      | Frequency |
|---------------------|-----------|
| Age                 | 60.3 ± 17.8 |
| Gender              | 60% male, 40% female |
| Hypertension        | 44% |
| DM                  | 26% |
| Asthma              | 7% |
| CAD                 | 15% |
| COPD                | 7% |
| CHF                 | 8% |
| Cancer              | 7% |
| Immunosuppression   | 7% |
| CKD                 | 10% |
| None of the above   | 35% |

DM: diabetes mellitus, CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease, CHF: congestive heart failure, CKD: chronic kidney disease.

---

Figure 2 Examples showing a range of CXR severity scores, which include extent and opacity scores. The two numbers for each are for the right and left lung. Arrows indicate region of ground glass opacities or/and airspace consolidations.
patients were analysed separately; however, the extent score correlated weakly with the length of hospital stay when regular ward patients and ICU patients were analysed together (R=0.13, p<0.05) while the opacity score was not (R=0.08, p>0.05). CXR scores were not associated with the duration on ventilator either (R=0.02 for geographic score and R=0.03 for opacity score, p>0.05). The extent score correlated weakly with duration of symptoms prior to ED visit (R=0.11, p<0.05) while the opacity score was not (R=0.09, p>0.05). There were no association of CXR scores with age (p>0.05) or sex (p>0.05).

Discussion

This study investigated whether the initial CXR scores inform COVID-19 status, ICU admission, need for ventilation, mortality, length of hospitalisation, and duration on ventilator. CXR scores were found to be associated with COVID-19 status, ICU admission, need for ventilation, but not with mortality after accounting for code status, length of hospitalisation, or duration on ventilator. A unique CXR scoring system was used in the present study. Different CXR scoring systems have been used to evaluate COVID-19 lung infection, some more sophisticated and some simpler. The RALE score, which is more sophisticated, is based on the sum of product of geographical extent and degree of opacity from different lung zones, and has been used to evaluate for severity of lung oedema and adopted to score CXR in evaluating COVID-19 lung infection. Several other simpler scoring systems did not take degree of opacity into consideration. The present scoring system also used both geographic extent and degree of opacity, but to make the system simpler, the lungs were not divided into different zones. The scoring system is relatively easy to use, has a reasonable dynamic range, and has high inter-rater agreement. Interestingly, the extent score and opacity score were highly correlated. The opacity scores generally yielded higher odds ratios than extent scores for clinical outcomes. This suggests that degree of opacity likely reflects disease severity better than the extent of lung infection. This is consistent with CXR and CT findings showing COVID-19 pneumonia progressing from ground-glass opacity to consolidation. The sum and product of the two scores was also investigated. The rationale for using the sum of the score is that the two scores were independently scored, and it is possible that their linear combination could add information. The rationale for using the product of the two scores is that it is possible that their geometric weighted average (extent and magnitude of opacity) could add information when combined linearly together. It is not clear whether individual scores, linear combination, or geometric combination yielded better results. Surprisingly, the sum and product of the two scores yielded similar conclusions, but did not yield better odds ratios than individual scores alone, suggesting that they might not add value. It would be useful to have a CXR reporting template that can be employed with a practical scoring system embedded in, which could help integration of the scoring system in the clinical workflow.

The initial CXR scores were associated COVID-19 status. This finding suggests that CXR scores can be used in conjunction with clinical observation and laboratory results for triage and management of suspected COVID-19 patients while waiting for RT-PCR results. The present results are inconsistent with Wong et al. who reported no differences in CXR scores between COVID-19 positive and negative patients. A possible explanation could be their small sample size (58 COVID-19 positive patients and six COVID-19 negative patients). There are differences in the scoring systems. Wong et al. only took into consideration the extent score, which is similar to the present extent score; however, there was a statistically significant difference in the extent score between COVID-19 positive versus negative patients. There is no significant difference between the present study and Wong et al. regarding when the CXRs were acquired. In the present study, CXRs were taken within the first 3 days of the ED visit with the majority (90%) of the CXRs taken on the day of ED visit. In Wong et al., 94% CXRs were taken at the ED presentation and 6% were taken within 48 h.

Table 2
Comparison of CXR scores and distribution of age, gender, and co-morbidities between COVID-19 negative group and COVID-19 positive group.

|                      | COVID-19 negative (n=59) | COVID-19 positive (n=441) | Adjusted p-value | Unadjusted p-value | Odds ratio (95% CI) |
|----------------------|-------------------------|---------------------------|------------------|--------------------|---------------------|
| Extent score (0–8)   | 2.4±2.2                 | 4.1±2.2                   | <0.001           | 1.49 (1.27–1.75)   |
| Opacity score (0–8)  | 2.0±1.6                 | 3.3±1.6                   | <0.001           | 1.75 (1.42–2.15)   |
| Sum of extent and opacity score (0–16) | 4.5±3.6 | 7.4±3.6 | <0.001 | 1.29 (1.17–1.41)  |
| Product of extent and opacity score (0–64) | 7.8±9.6 | 16.2±12.5 | <0.001 | 1.08 (1.05–1.13)  |
| Age                  | 62.1±21.6               | 60.1±17.3                 | 0.43             |                    |
| Gender (% of Male)   | 53%                     | 61%                       | 0.20             |                    |
| Hypertension         | 53%                     | 43%                       | 0.18             |                    |
| DM                   | 20%                     | 27%                       | 0.26             |                    |
| Asthma               | 14%                     | 6%                        | 0.05             |                    |
| CAD                  | 24%                     | 14%                       | 0.05             |                    |
| COPD                 | 12%                     | 7%                        | 0.17             |                    |
| CHF                  | 24%                     | 5%                        | <0.01            |                    |
| Cancer               | 19%                     | 6%                        | <0.01            |                    |
| Immunosuppression    | 14%                     | 6%                        | 0.05             |                    |
| CKD                  | 17%                     | 9%                        | 0.05             |                    |

DM: diabetes mellitus, CAD: coronary artery disease, COPD: chronic obstructive pulmonary disease, CHF: congestive heart failure, CKD: chronic kidney disease.
Table 3 (a) Comparison of CXR scores between the regular ward group and the ICU group; (b) distribution of age, gender and co-morbidities between regular ward group and ICU group; and (c) between patients not on ventilation and patients on ventilation.

| (a) | Regular ward patients (n=255) | ICU patients (n=176) | Adjusted p-value | Adjusted Odds ratio (95% CI) |
|-----|-------------------------------|----------------------|------------------|-----------------------------|
| Extent score (0–8) | 3.8±2.2 | 4.6±2.2 | <0.001 | 1.19 (1.09–1.31) |
| Opacity score (0–8) | 3.1±1.5 | 3.7±1.6 | 0.001 | 1.26 (1.10–1.44) |
| Sum of extent and opacity score (0–16) | 6.8±3.5 | 8.3±3.6 | <0.001 | 1.12 (1.06–1.19) |
| Product of extent and opacity score (0–64) | 14.1±11.5 | 19.7±13.3 | <0.001 | 1.04 (1.02–1.05) |

| (b) | Regular ward patients (n=255) | ICU patients (n=176) | Unadjusted p-value |
|-----|-------------------------------|----------------------|-------------------|
| Age | 60.9±18.4 | 59.6±15.5 | 0.44 |
| Gender (% of male) | 57% | 68% | 0.03 |
| Hypertension | 42% | 47% | 0.34 |
| DM | 25% | 31% | 0.16 |
| Asthma | 6% | 7% | 0.53 |
| CAD | 15% | 12% | 0.38 |
| COPD | 8% | 5% | 0.22 |
| CHF | 7% | 4% | 0.24 |
| Cancer | 7% | 4% | 0.24 |
| Immunosuppression | 7% | 6% | 0.68 |
| CKD | 10% | 7% | 0.39 |

| (c) | Non-ventilated (n=281) | Ventilated (n=150) | Adjusted p-value | Adjusted Odds ratio (95% CI) |
|-----|------------------------|---------------------|------------------|-----------------------------|
| Extent score (0–8) | 3.8±2.2 | 4.3±2.1 | <0.001 | 1.22 (1.11–1.35) |
| Opacity score (0–8) | 3.2±1.5 | 3.5±1.5 | 0.009 | 1.21 (1.05–1.38) |
| Sum of extent and opacity score (0–16) | 6.9±3.5 | 7.8±3.4 | <0.001 | 1.12 (1.05–1.19) |
| Product of extent and opacity score (0–64) | 14.6±11.7 | 17.5±11.9 | <0.001 | 1.03 (1.02–1.05) |

Table 4 Comparison of CXR scores (a) between survivors and non-survivors group on the regular ward, (b) between survivors and non-survivors group in the ICU, and (c) between survivors and non-survivors group in the ICU who were full code only.

| (a) | Regular ward survivors (n=227) | Regular ward non-survivors (n=28) | Adjusted p-value | Adjusted Odds ratio (95% CI) |
|-----|-------------------------------|-----------------------------------|------------------|-----------------------------|
| Extent score (0–8) | 3.6±2.2 | 5.0±1.9 | 0.001 | 1.73 (1.25–2.40) |
| Opacity score (0–8) | 3.0±1.4 | 4.0±1.6 | 0.001 | 2.18 (1.37–3.48) |
| Sum of extent and opacity score (0–16) | 6.6±3.4 | 9.0±3.1 | 0.001 | 1.48 (1.18–1.86) |
| Product of extent and opacity score (0–64) | 13.3±10.9 | 21.3±14.0 | 0.001 | 1.09 (1.04–1.15) |

| (b) | ICU survivors (n=98) | ICU non-survivors (n=59) | Adjusted p-value | Adjusted Odds ratio (95% CI) |
|-----|----------------------|--------------------------|------------------|-----------------------------|
| Extent score (0–8) | 4.6±2.2 | 4.7±2.0 | 0.133 | 1.17 (0.95–1.43) |
| Opacity score (0–8) | 3.6±1.6 | 3.8±1.6 | 0.023 | 1.38 (1.05–1.82) |
| Sum of extent and opacity score (0–16) | 8.2±3.7 | 8.5±3.3 | 0.050 | 1.13 (1.00–1.29) |
| Product of extent and opacity score (0–64) | 19.4±12.9 | 20.0±13.5 | 0.034 | 1.04 (1.00–1.07) |

| (c) | ICU survivors, full code (n=92) | ICU non-survivors, full code (n=16) | Adjusted p-value | Adjusted Odds ratio (95% CI) |
|-----|-------------------------------|-------------------------------------|------------------|-----------------------------|
| Extent score (0–8) | 4.7±2.2 | 4.5±2.1 | 0.983 | 1.01 (0.73–1.41) |
| Opacity score (0–8) | 3.7±1.6 | 3.7±1.9 | 0.714 | 1.09 (0.70–1.68) |
| Sum of extent and opacity score (0–16) | 8.4±3.6 | 8.2±3.7 | 0.827 | 1.02 (0.84–1.25) |
| Product of extent and opacity score (0–64) | 19.9±12.9 | 19.2±14.2 | 0.647 | 1.01 (0.96–1.07) |

CXR: chest radiograph, ICU: intensive care unit.

Previous studies did not account for code status. As a result, it is challenging to determine whether patients who died would have survived if more aggressive measures had been taken among patients assigned to comfort care only. Similarly, no correlations were found between initial CXR scores and length of hospital stay for regular ward patients or ICU patients, and between initial CXR scores and duration on mechanical ventilator. These findings are not surprising because these outcomes are far downstream from the patients’ status in the ED, although such an association might exist depending on patient cohorts. The present results are consistent with Towse et al. who reported CXR scores were not associated with length of hospital stay, but inconsistent with Kim et al. who reported CXR scores were associated with length of hospital stay. Possible explanations for this discrepancy could be due to differences in patient...
cohort. Interestingly, there was a weak correlation between the extent score and length of hospital stay when combining regular ward and ICU patients, but did not find a correlation when analysing regular ward and ICU patients separately. One possible explanation is that ICU patients tend to have higher CXR scores and longer length of hospitalisation than regular ward patients.

This study has several limitations. First, although the present CXR score system is easy to use with good inter-rater agreement, there are more sophisticated score schemes that could reflect disease severity better. Second, the present study used only initial CXRs. Longitudinal CXR scoring is needed to better inform clinical trajectory and outcome. Third, although several co-morbidities were included in the study, body mass index (BMI) was not included, which is a known risk factor for COVID-19. Fourth, although the majority of the CXRs (90%) were acquired on the day of ED presentation and presumably before the patients received interventions, it was hard to track whether the patients received interventions prior to CXR acquisition, which could have affected the CXR scores. This is a retrospective study from a single institution. These findings need to be repeated using multiple institutional data to test generalisability. Machine learning approaches to classify COVID-19 lung infection on CXR and stage COVID-19 disease severity on CXR have also been recently reported. Future studies could incorporate laboratory variables to better inform clinical disease trajectory and outcome.

In conclusion, initial CXR scores in the ED are associated with positive COVID-19 status, ICU admission, and need for invasive mechanical ventilation. Initial CXR scores have prognostic value and offer important information that could be used to facilitate identification of high-risk patients and triage and manage patients suspected of or diagnosed with COVID-19, especially when combined with other clinical data, such as vital signs and blood tests.

**Conflict of interest**

The authors declare no conflict of interest.

**References**

1. Li Q, Guan X, Wu P, et al. Early transmission dynamics in Wuhan, China, of novel coronavirus-infected pneumonia. *N Engl J Med* 2020;**382**(13):1199–207.
2. Hui DS, F IA, Madani TA, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health — the latest 2019 novel coronavirus outbreak in Wuhan, China. *Int J Infect Dis* 2020;**91**:264–6.
3. Wang W, Xu Y, Gao R, et al. Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* 2020;**323**(18):1843–4.
4. Johns Hopkins University. COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University. Global Map; 2020. Available at, https://coronavirus.jhu.edu/map.html. [Accessed 11 July 2020].
5. Tang YW, Schmitz JE, Persing DH, et al. Laboratory diagnosis of COVID-19: current issues and challenges. *J Clin Microbiol* 2020;**58**(6):e00512-20.
6. Valen AB, Sture C. Negative nasopharyngeal swabs early in the course of COVID-19. *Tidsskr Nor Laegeforen* 2020;**140**(9). https://doi.org/10.4045/tidsskr.20.0356.
7. Wise J, Covid-19: lateral flow tests miss over half of cases, Liverpool pilot data show. *BMJ* 2020;**371**:m4848.
8. Xu X, Yu C, Qu J, et al. Imaging and clinical features of patients with 2019 novel coronavirus SARS-CoV-2. *Eur J Nucl Med Mol Imaging* 2020;**47**(5):1275–80.
9. Jacobi A, Chung M, Bernheim A, et al. Portable chest X-ray in coronavirus disease-19 (COVID-19): a pictorial review. *Clin Imaging* 2020;**64**:35–42.
10. Kim HW, Capaccione KM, Li G, et al. The role of initial chest X-ray in triaging patients with suspected COVID-19 during the pandemic. *Emerg Radiol* 2020 Dec;**27**(6):617–21.
11. Toussie D, Voutsinas N, Finkelstein M, et al. Clinical and chest radiography features determine patient outcomes in young and middle age adults with COVID-19. *Radiology* 2020;Oct;**297**(1):E197–206.
12. Borghesi A, Zigliani A, Golemi S, et al. Chest X-ray severity index as a predictor of in-hospital mortality in coronavirus disease 2019: a study of 302 patients from Italy. *Int J Infect Dis* 2020;**96**:291–3.
13. Cozzi D, Albanesi M, Cavigli E, et al. Chest X-ray in new coronavirus disease 2019 (COVID-19) infection: findings and correlation with clinical outcome. *Radiol Med* 2020;**125**(8):730–7.
14. Hui TCH, Khoo HW, Young BE, et al. Clinical utility of chest radiography for severe COVID-19. *Quint Imaging Med Surg* 2020;**10**(7):1540–50.
15. Wong HYF, Lam HYS, Fong NA, et al. Frequency and distribution of chest radiographic findings in COVID-19 positive patients. *Radiology* 2019;**201160**.
16. Warren MA, Zhao Z, Koyama T, et al. Severity scoring of lung oedema on the chest radiograph is associated with clinical outcomes in ARDS. *Thorax* 2018;**73**(9):840–6.
17. Bernheim A, Mei X, Huang M, et al. Chest CT findings in coronavirus disease-19 (COVID-19): relationship to duration of infection. *Radiology* 2020;**299**(3):200463.
18. Luo X, Zhou W, Yan X, et al. Prognostic value of C-reactive protein in patients with COVID-19. *Clin Infect Dis* 2020 Nov 19;**71**(16):2174–9.
19. Hussain L, Nguyen T, Li H, et al. Machine-learning classification of texture features of portable chest X-ray accurately classifies COVID-19 lung infection. *Biomed Eng Online* 2020;**19**(1):88.
20. Kikikisetti S, Zhu J, Shen B, et al. Deep-learning convolutional neural networks with transfer learning accurately classify COVID-19 lung infection on portable chest radiographs. *PeerJ* 2020;**8**:e10305.
21. Zhu J, Shen B, Abbasi A, et al. Deep transfer learning artificial intelligence accurately stages COVID-19 lung disease severity on portable chest radiographs. *PLoS One* 2020;**15**(7):e0236621.
22. Cohen JP, Dao I, Roth K, et al. Predicting COVID-19 Pneumonia Severity on Chest X-ray With Deep Learning. *Cureus* 2020;**12**(7):e9448.
23. Zhu JS, Ge P, Jiang C, et al. Deep-learning artificial intelligence analysis of clinical variables predicts mortality in COVID-19 patients. *J Am Coll Emerg Physicians* 2020;**1**:1364–73.
24. Zhao Z, Chen A, Hou W, et al. Prediction model and risk scores of ICU admission and mortality in COVID-19. *PLoS One* 2020;**15**(7):e0236618.
25. Li X, Ge P, Zhu J, Li H, et al. Deep learning prediction of likelihood of ICU admission and mortality in COVID-19 patients using clinical variables. *PeerJ* 2020;**8**:e10337.